6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
observed O
in O
clinical O
trials O
were O
application O
site O
reactions O
, O
which O
occurred O
in O
less O
than O
1 O
% O
of O
subjects O
. O

( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Valeant O
Pharmaceuticals O
North O
America O
LLC O
at O
1-800-321-4576 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
, O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
three O
Phase O
3 O
clinical O
trials O
, O
616 O
subjects O
were O
exposed O
to O
LUZU O
Cream O
, O
1 O
% O
: O
305 O
with O
interdigital B-Not_AE_Candidate
tinea I-Not_AE_Candidate
pedis I-Not_AE_Candidate
and O
311 O
subjects O
with O
tinea B-Not_AE_Candidate
cruris I-Not_AE_Candidate
. O

Subjects O
with O
interdigital B-Not_AE_Candidate
tinea I-Not_AE_Candidate
pedis I-Not_AE_Candidate
or O
tinea B-Not_AE_Candidate
cruris I-Not_AE_Candidate
applied O
LUZU O
Cream O
, O
1 O
% O
or O
vehicle O
cream O
once O
daily O
for O
14 O
days O
or O
7 O
days O
, O
respectively O
, O
to O
affected O
and O
adjacent O
areas O
. O

During O
clinical O
trials O
with O
LUZU O
Cream O
, O
1 O
% O
, O
the O
most O
common O
adverse O
reactions O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
which O
occurred O
in O
less O
than O
1 O
% O
of O
subjects O
in O
both O
the O
LUZU O
and O
vehicle O
arms O
. O

Most O
adverse O
reactions O
were O
mild O
in O
severity O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postmarketing O
use O
of O
luliconazole O
cream O
, O
1 O
% O
: O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
and O
cellulitis B-OSE_Labeled_AE
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

